Informace o publikaci

Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium.

Autoři

CLEMENS Eva VAN DEN HEUVEL-EIBRINK Marry M. MULDER Renée L. KREMER Leontien C. M. HUDSON Melissa M. SKINNER Roderick CONSTINE Louis S. BASS Johnnie K. KUEHNI Claudia E. LANGER Thorsten VAN DALEN Elvira C. BARDI Edith BONNE Nicolas-Xavier BROCK Penelope R BROOKS Beth CARLETON Bruce CARON Eric CHANG Kay W JOHNSTON Karen KNIGHT Kristin NATHAN Paul C. ORGEL Etan PRASAD Pinki K. ROTTENBERG Jan SCHEINEMANN Katrin DE VRIES Andrica C. H. WALWYN Thomas WEISS Annette ZEHNHOFF-DINNESEN Antoinette am COHN Richard J LANDIER Wendy

Rok publikování 2019
Druh Článek v odborném periodiku
Časopis / Zdroj The Lancet Oncology
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30858-1/fulltext
Doi http://dx.doi.org/10.1016/S1470-2045(18)30858-1
Klíčová slova ototoxicity; surveillance; guidelines; childhood adolescent and young adults cancer survivors
Přiložené soubory
Popis Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems—such as speech and language, social–emotional development, and learning difficulties—for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.